

## **ASX Announcement**

### **13 March 2024**

### ***Non-Renounceable Rights Issue Offer – Closing Date Reminder***

Elixinol Wellness Limited (**Elixinol Wellness** or the **Company**) (**ASX:EXL**) reminds eligible shareholders that the fully underwritten, non-renounceable entitlement offer announced to ASX on 12 February 2024 (**Entitlement Offer**) will close at **5.00pm (AEDT)** on **Friday, 15 March 2024**.

The Entitlement Offer price of 0.5 cents for one (1) new fully paid ordinary share (**New Share**) for every one (1) share held, together with one (1) free attaching listed option for every two (2) New Shares subscribed for and issued (**Attaching Options**). The Attaching Options will be exercisable at 0.75 cents each and expire 36 months from the date of issue (**New Options**). The Company will apply for the Attaching Options to be quoted on the ASX. Furthermore, the sub-underwriter to the Entitlement Offer will receive a one (1) for two (2) sub-underwriter options for each share sub-underwritten (**Sub-underwriter Options**), issued on the same terms as the Attaching Options. The Sub-Underwriter Options will be subject to shareholder approval, to be sought as soon as practicable.

The Entitlement Offer price of 0.5 cents represents a discount of:

- 50.0% to the Company's last traded price on 9 February 2024 (\$0.01); and
- 51.1% discount to the 10-day VWAP (\$0.0102) of the Company's shares.

Eligible Shareholders also have the opportunity to apply for additional New Shares and New Options (**Top-up Securities**) in addition to their pro-rata entitlement.

Eligible Shareholders who have elected to receive electronic communications, should have received an email containing instructions about how to view and download a copy of the Company's prospectus dated 19 February 2024, in relation to the Entitlement Offer (**Prospectus**) as well as instructions on how to apply for the Entitlement Offer.

Eligible Shareholders who have elected to receive hard copy communications, should have received via post, a letter containing instructions about how to view and download a copy of the Prospectus and a personalised entitlement and acceptance form online.

If you have any queries regarding the Entitlement Offer, please contact your professional adviser or the offer information line on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia) at any time between 8.30am and 7.00pm (AEDT) on Monday to Friday until the closing date of the Entitlement Offer.

This document was authorised to be given to the ASX by the Group CEO and Managing Director of the Company.

**Investor relations please contact:**

Ron Dufficy, Group CEO and Managing Director  
[ron.dufficy@elixinolwellness.com](mailto:ron.dufficy@elixinolwellness.com)

**About Elixinol Wellness**

Elixinol Wellness Limited (ASX: EXL) is a pioneer in the global hemp industry, innovating, marketing and selling hemp and other plant-derived food, skincare and nutraceutical products:

- In Australia, EXL operates a vertically integrated business which produces, manufactures, exports and distributes a range of sustainable and plant-based nutrition brands including Hemp Foods Australia, Mt Elephant, Field Day and The Australian Superfood Company. EXL sells to grocery, wholesale, e-commerce and white label customers.
- In the Americas, innovating, marketing and selling high quality Elixinol branded hemp and other plant derived nutraceutical and skincare products based in Colorado, USA.
- In the United Kingdom, Japan, Brazil, Mexico and South Africa, branded hemp and other plant-derived products are available to consumers via exclusive distribution and/or trademark and know-how licensing agreements.

See more at [www.elixinolwellness.com](http://www.elixinolwellness.com)